$6.42
+1.1%Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial stress indicators: Both liquidity and leverage metrics raise concerns. The company may face challenges meeting obligations and should focus on strengthening its balance sheet.
TTRX • NASDAQ
| Turn Therapeutics Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
ASSETS | |||
CURRENT ASSETS | |||
5.1M | 872.6K | 1.2M | |
5.1M | 872.6K | 1.2M | |
120.3K | 0.0 | 0.0 | |
0.0 | 225.3K | 20.8K | |
5.2M | 1.1M | 1.2M | |
NON-CURRENT ASSETS | |||
0.0 | 120.5K | 33.2K | |
922.2K | 821.9K | 769.9K | |
922.2K | 821.9K | 769.9K | |
6M | 8.6K | 8.6K | |
7M | 951K | 811.7K | |
12.2M | 2M | 2M | |
LIABILITIES | |||
CURRENT LIABILITIES | |||
2.9M | 0.0 | 0.0 | |
2.9M | 0.0 | 0.0 | |
46.3K | 40.7K | 25.2K | |
3M | 667.3K | 464.6K | |
6M | 707.9K | 489.8K | |
NON-CURRENT LIABILITIES | |||
1.4M | 1.4M | 1.4M | |
1.5M | 1.5M | 1.4M | |
80.4K | 121K | 25.2K | |
7.5M | 2.2M | 1.9M | |
SHAREHOLDERS' EQUITY | |||
2.9K | 1.3K | 1.3K | |
28.1M | 19M | 17.5M | |
-22.4M | -19.2M | -17.4M | |
-1.1M | 0.0 | 0.0 | |
4.7M | -177.4K | 85.8K | |
4.7M | -177.4K | 85.8K | |
SUMMARY | |||
12.2M | 2M | 2M | |
80.4K | 121K | 25.2K | |
-5M | -751.6K | -1.2M | |
28,022,826 | 28,022,826 | 28,022,826 |
TTRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 23, 2026 | 2026 |
Continue your TTRX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.